The European Commission has approved Eli Lilly‘s monthly infusion therapy Kisunla (donanemab) for adults with early symptomatic…
Articles by Marisa Wexler, MS
September is World Alzheimer’s Month, and the global Alzheimer’s disease community is looking to raise awareness and combat stigma…
An experimental oral therapy called blarcamesine appears to slow the progression of Alzheimer’s disease, reducing the rate of cognitive…
June is Alzheimer’s and Brain Awareness Month, and the Alzheimer’s Association is urging patients, caregivers, and supporters to “take…
Axsome Therapeutics plans this year to ask the U.S. Food and Drug Administration (FDA) to approve its oral therapy…
November is National Alzheimer’s Awareness Month, and the Alzheimer’s Foundation of America (AFA) is encouraging those impacted by…
Alzamend Neuro has determined the maximum tolerated dosage of AL001, its experimental lithium therapy for Alzheimer’s disease and other…
Treatment with CT1812, previously called Elayta, slowed the decline of cognitive function among adults with mild to moderate…
The U.S. Food and Drug Administration (FDA) has approved the oral therapy Zunveyl (benzgalantamine), previously known as…
The safety and effectiveness of oral therapy candidate buntanetap are comparable in people with early Alzheimer’s disease regardless…